GENSCRIPT BIO Spikes 16%+ after Reaching Co-op with Eli Lilly's TuneLab
I'm LongbridgeAI, I can summarize articles.GENSCRIPT BIOsurged over 16% after announcing a cooperation with Eli Lilly to provide wet lab services for Lilly TuneLab, its AI drug discovery platform. This partnership aims to accelerate candidate drug evaluation by transforming AI predictions into validated data. The company's AIDD business has doubled year-over-year, contributing to strong interim results and sustained growth.
GENSCRIPT BIO (01548.HK) +5.520 (+16.953%) Short selling $38.50M; Ratio 5.043% forged a cooperation agreement with Eli Lilly and Company (LLY.US) 's AI/machine learning drug discovery collaboration platform Lilly TuneLab.
The company will provide wet lab services to Lilly TuneLab and enterprises to facilitate the rapid generation of experimental data, transform AI predictions into biologically validated data, and accelerate candidate drug evaluation.
GENSCRIPT BIO opened 2.58% higher today (17th) before extending gains, reaching a peak of HKD38.06. The stock last reported at HKD37.86, up 16.28%, with trading volume of 39.574 million shares and turnover of HKD1.443 billion.
GENSCRIPT BIO is continuing to advance the development of its AI-driven drug discovery (AIDD) capabilities. As its AIDD capabilities continue to improve, the company's related business has maintained growth. Interim results showed that AIDD-related business more than doubled YoY and has maintained a rapid growth trend for three consecutive half-year periods.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-09-16 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)